A sponsor of an early-phase clinical trial who receives a decision from the medicines regulator within 14 days has, on that same day, finished only the first stage of a longer wait. Contracts, site approvals, pharmacy arrangements and the recruitment of patients all lie ahead, and none of them belongs to the Medicines and Healthcare products Regulatory Agency.

That gap sits at the centre of the agency's newly published 2030 Strategy. It halves the initial assessment target for qualifying Phase 1 trials to 14 days, introduces a premium service that cuts scientific advice from 90 days to 45, promises quicker decisions on generics and biosimilars and commits to an AI-enabled protocol checker for sponsors. Taken together these amount to service guarantees, and the pharmaceutical industry has welcomed them as such, with the ABPI's chief executive remarking on how explicitly performance will be measured.

The credibility of those guarantees has a history. The agency's chief executive has acknowledged that it struggled to meet its performance targets in recent years, and its latest annual report describes a year of strong delivery and a financial surplus. A regulator in recovery is now being precise about its own timings at a moment when ministers want life sciences investment and have made regulatory pace central to attracting it.

The difficulty is that the strategy can bind only the MHRA. Speed at approval produces patient benefit when the health service can commission, procure, adopt and monitor what has been approved, and the NHS reaches that stage with long waiting lists and trusts working to tight financial limits.

Research capacity is the most immediate test. Companies decide where to run trials largely on how fast sites open and participants enrol, so a quicker first assessment simply shifts the focus to whichever step is slowest. The updated clinical trials legislation and the aligned digital application journey that the Health Research Authority describes should remove some delay, although delivery rests with individual trusts whose research teams compete with clinical demand for the same staff time.

Access to medicines raises the same issue at the other end of the process. The agency and NICE have launched an aligned pathway intended to bring some medicines to patients up to six months sooner, and the strategy promises closer working between the two bodies. A faster licence offers little to a patient if funding decisions, commissioning and local formulary approval take as long as they did before. Industry will watch those steps as closely as it watches the regulator, because investment decisions weigh the whole route to market.

The AI commitments carry a further implication for NHS leaders. Alongside a new Centre for AI and Digital Health, the agency plans an adaptive regulatory framework for AI as a medical device, and a separate action plan on AI in medicines development is due in 2027  will define what developers must demonstrate before products reach clinical settings. Trusts and integrated care boards buying ambient voice tools and decision support systems will find those expectations shaping their procurement specifications and the assurance they demand from suppliers. The agency's plan to work with the Health Data Research Service on real-time safety surveillance depends on NHS data that is accessible and consistent, and provider data quality remains uneven.

Patients meet the strategy in a different place. Commitments to expand criminal enforcement against illegal medicines, to work with online platforms and marketplaces, and to make Yellow Card reporting simpler address a public that increasingly buys treatments online and relies on the regulator when something goes wrong. The promised Women's Health Plan and greater diversity in clinical studies will be judged by who actually appears in trial populations, and by whether NHS research sites are resourced to recruit them.

The MHRA has set itself a clock and published it. The rest of the system has set itself no equivalent. If ministers want faster regulation to produce earlier treatment and inward investment, the next set of public targets belongs to the bodies that take over once the regulator has finished, with the same open measurement the agency has now accepted for itself. Until that happens, faster regulation will leave patients and sponsors waiting at the next stage.